Psychiatric Medication Users by Age and Sex in the United States, 1999–2018

Michael E. Johansen, MD, MS

Purpose: This study aimed to determine the rates of psychiatric medication users in the United States between 1999 to 2018 for different medication categories by age and sex.

Methods: The 1999 to 2002, 2006 to 2009, and 2015 to 2018 Medical Expenditure Panel Surveys (MEPS) were used for the analysis. All individuals with a valid age were included. Any antidepressant, benzodiazepine, attention deficit hyperactivity disease (ADHD) medication, antipsychotics, and mood stabilizer report use was defined as a medication user. Separate multivariable logistic regression predicted medication users by age with restricted cubic splines by sex, medication category, and year category (1999 to 2002, 2006 to 2009, and 2015 to 2018). In addition, the rate of prescribing to males and females at different ages was determined for medication categories.

Results: Rates of any psychiatric medication users increased during the study period. Females had higher rates of medication users around 20 years of age. Rates of antidepressant users increased over time and were higher for females after earlier adolescence. Rates of benzodiazepine users were higher for females, increased after 1999 to 2002, and had consistent patterns of use over time. Antipsychotic and mood stabilizer user rates were lower than other categories. Adolescent antipsychotic users markedly decreased between 2006 to 2009 and 2015 to 2018. Rates of ADHD medication users increased over time, particularly among younger adults between 25 and 50 years of age.

Conclusion: The rates of individuals reporting the use of any psychiatric medications increased over the last few decades. Rates and patterns of medication users have large variations by medication category, age, and sex, but these patterns of use were stable for most medication categories. (J Am Board Fam Med 2021;34:732–740.)

Keywords: Attention Deficit Disorder With Hyperactivity, Benzodiazepines, Health Services Research, Logistic Regression, Mental Health Services, Primary Health Care, Psychiatry, Psychopharmacology, Psychotropic Drugs, Surveys and Questionnaires

Introduction

Previous studies have investigated the use of psychiatric medications in the United States.1–8 However, these studies did not clearly identify changes in medication use over time by age and sex. Therefore, the proportion of the population by age and sex that used any psychiatric medication and by classes of psychiatric medication between 1999 to 2018 was investigated.

Methods

This descriptive study included individuals with an applicable age from the 1999 to 2002, 2006 to 2009, and 2015 to 2018 Medical Expenditure Panel Survey (MEPS)9 were included in the analysis. The MEPS is sponsored by the Agency of Health care Research and Quality (AHRQ) and is nationally representative of the noninstitutionalized population of the United States. The survey is conducted through 5 interviews over 2 years on 2 overlapping cohorts and includes a complex array of methods of collecting and confirming utilization data.8

Psychiatric medications were identified by name and grouped into antidepressants (selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, trazodone, nefazodone, vilazodone, bupropion, and
mirtazapine), benzodiazepines (including zolpidem, eszopiclone, and temazepam), antipsychotics (both typical and atypical), mood stabilizers (lithium, carbamazepine, oxcarbazepine, valproic acid, and lamotrigine), attention deficit hyperactivity disorder (ADHD) medications (stimulants and atomoxetine), and buspirone. A medication user was defined as any reported fill of a medication in the defined classes. Buspirone was only included in the any psychiatric medication analysis.

The proportion of individuals using any psychiatric medication, any antidepressant, any benzodiazepine, any antipsychotic, any mood stabilizer, and any ADHD medication during a year was determined using multivariable logistic regressions by sex and year grouping (1999 to 2002, 2006 to 2009, and 2015 to 2018). Restricted cubic splines with 5 knots were used for psychiatric medications, antidepressants, benzodiazepines, and ADHD medication and 4 knots were used for antipsychotics and mood stabilizers. The “adjustrcspline” command was then utilized to construct post-regression estimates.

The rate ratio of female-to-male users was determined for each drug category by dividing the rates for the 6 categories within each decade of life. Given small sample sizes in certain age ranges, some medication classes were grouped into larger age ranges. Antipsychotics, mood stabilizers, and benzodiazepines were grouped as 0 to 19 years of age. ADHD medications were top coded at 50 or more years of age. Mood stabilizers and antipsychotics were top coded as 60 or more years of age.

Analyses were conducted using complex survey weighting in STATA version 15 (STATA Corporation). The Ohio Health Institutional Review Board ruled the study exempt.

**Results**

The sample included 386,977 individuals for the selected years between 1999 to 2018. Overall, the proportion of individuals reporting any psychiatric medication increased from 10.7% (95% confidence interval (CI), 10.5 to 11.0) in 1999 to 2002 to 15.6% (95%CI, 15.1 to 16.0) in 2015 to 2018. Rates of medication users of any psychiatric medication varied by age and sex. Rates of males who used a medication were higher before 20 years of age, but afterward, females were more likely to be medication users. The curves shifted upward following 1999 to 2002. Otherwise, small changes were seen in use patterns by sex. For instance, the proportion of females between 15 to 30 years and...
>60 years had increases in rates of use between 2006 to 2009 and 2015 to 2018 (Figure 1).

**Anti-depressants**

Antidepressant users during a year increased from 7.3% (95%CI, 7.1 to 7.5) in 1999 to 2002 to 10.9% (95%CI, 10.5 to 11.3) in 2015 to 2018. Females more often reported antidepressant use than males by around 10 years of age. The highest rates of users were females aged between 55 to 75 years. Rates of male antidepressant users continued to increase with increasing age in 2015 to 2018, while rates attenuated for females after 75 years of age for all time periods. The female and male rate of users increased between 1999 to 2002 and 2015 to 2018 particularly between those 15 to 30 years and over 40 years (Figure 2).

**Benzodiazepines**

Rates of users were consistently higher for females compared with males. The rate increased at a younger age for females than males with the largest relative difference in the rate of users at around 30 years of age. Rates of users clearly increased with age for both sexes with similar patterns in rates in all 4-year categories. Rates of users increased between 1999 to 2002 and 2006 to 2009, but notably less so between 2006 to 2009 and 2015 to 2018. There was no strong evidence of a decline in users among individuals aged >75 years (Figure 3).

**Antipsychotics**

Rates of antipsychotic users were notably lower than antidepressants and benzodiazepines. The patterns of use also changed over the 3 time periods. For instance, among young males (<25 years), the rates of use were low from 1999 to 2002, then notably increased during 2006 to 2009 before a dramatic reduction by 2015 to 2018. Females between 25 to 65 years had a notable increase in rates of use following 1999 to 2002. No notable changes in rates of use were identified among individuals older than 75 years (Figure 4).

**Mood stabilizers**

Rates of users were similar to antipsychotics for both men and women. Rates appeared to have less change than many other medication categories. Rates of users did not seem to have had much change in males or females <25 years or >60 years. However, rates of use were increased among individuals between 35 to 55 years. Rates of mood stabilizer users were similar between females and males at most age ranges, but small differences were unlikely to be identified due to limited sample size (Figure 5).

Figure 2. Proportion of Individuals Reporting Any Anti-Depressant Medication by Age, Sex, and Time Period. The figure represents the proportion of individuals reporting any antidepressant medication during a year. Separate multivariable logistic regression used by sex and time period. Restricted cubic splines were utilized to model age. The dashed lines represented 95% confidence intervals.
ADHD medications
Rates of ADHD medication users were higher among males than females in individuals younger than 20 years with the differences by sex being notably less after that age range in 2015 to 2018. Among females, rates increased through the 3 time periods. Among males, there was a notable increase among individuals <20 years between 1999 to 2002.

Figure 4. Proportion of Individuals Reporting Any Antipsychotic Medication by Age, Sex, and Time Period. The figure represents the proportion of individuals reporting any antipsychotic medication during a year. Separate multivariable logistic regression used by sex and time period. Restricted cubic splines were utilized to model age. The dashed lines represented 95% confidence intervals.
between 1999 to 2002 and 2015 to 2018 while patterns remained relatively stable. Between 2015 to 2018 more than 25% of females older than 50 years reported use of a psychiatric medication, while around 30% of females over 60 years reported a psychiatric medication. Females had higher rates of psychiatric medication users after 15 to 20 years related to a combination of changes in users within and between medication categories.

Clear patterns of medication users were identified for most medication categories by age and sex through the course of the study, which likely represents some combination of acceptance of medication, symptom burden, and differences in access to care. Patterns of use for antidepressants for both males and females showed higher rates compared with earlier time points particularly among individuals between 15 to 35 and >50 years of age. Rates of benzodiazepine users increased with age from 10 to 60 years of age with some attenuation in most years following 60 years. Importantly, a notable decline in the rate of antipsychotic users was identified among individuals <20 years, which was particularly apparent among males from 2015 to 2018. This decline was likely secondary to changes in recommendations. The rate of ADHD medication users peaked in the teenage years with a rapid drop
after adolescence. The most notable changes were the increase of the curve during teenage years as well as higher rates of medication users between 25 to 30 years throughout the study. These findings support both inter- and intragenerational changes in ADHD medication users.

The patterns of use for the most recent period (2015 to 2018) are visualized in Figure 7 and Figure 8.

Figure 7. Proportion of Individuals Reporting Medication Use by Age and Sex in 2015 to 2018. The figure represents the proportion of individuals reporting use of different medications during a year between 2015 to 2018. Separate multivariable logistic regression used by sex and medication category. Restricted cubic splines were utilized to model age.
The comparative rate of users for males and females had a relatively consistent pattern for antidepressants, benzodiazepines, and antipsychotics. However, the age when females were clearly more likely to be medication users in these categories varied by age. There was no clear difference in the rate of mood stabilizer users by sex at any age, while ADHD medication had a unique pattern among the examined medication categories.

These data raise deeper questions about the meaning and importance of rates of psychiatric medication users. Different people will likely have wildly different interpretations of the importance of these data. Some will proclaim that advancements in medical science (ie, medications) have improved the quality of life of millions, while others will see these data as evidence of intrinsic flaws in modern society. These debates will likely...
continue. These data raise more questions such as: why the rates of psychiatric medication users are as high as they are when the evidence surrounding most of these medications shows modest short-term effect sizes with meager long-term data?11–15

The study had numerous limitations. First, medication use is self-reported (and confirmed through pharmacies).16 Previous studies have found chronic medications are well reported, but short-term medications (ie, benzodiazepines or trazodone) might be less so.17 Second, 4-year periods were selected to compare, which could fail to recognize important changes between or within these time periods. Third, the use of restricted cubic splines could overfit changes in age. Fourth, many of these medications could be used for nonpsychiatric purposes, and, therefore, this study should be interpreted as such. Fifth, the mood stabilizer category is not well defined as these medications have different mechanisms of action. Sixth, age had to be categorized for the comparison rates of female-to-male due to difficulty in calculating confidence intervals with survey-weighted data using splines. Seventh, the composition of the population at different age ranges could be different over time. For instance, individuals with bipolar disorder and schizophrenia are known to have notably shorter life spans than individuals without these conditions.18–20 In addition, if life expectancy of these conditions has changed over the last few decades, findings from this study could be impacted. Eighth, consideration should be given to the changing racial and ethnic makeup of the United States during the study periods.

Conclusion

The rates of individuals reporting use of psychiatric medications have increased over the last couple of decades. Rates and patterns of medication users have large variations by medication category, age, and sex. Patterns of use were stable for most medication categories.

I would like to thank Raj Mehta, MD for comments on the manuscript.

To see this article online, please go to: http://jabfm.org/content/34/4/732.full.

References


